What is Omnicell's gross profit margin?

What is Omnicell's latest dividend and current dividend yield?

What factors drove the changes in Omnicell's revenue and profit?

What does Omnicell do and what are its main business segments?

What were the key takeaways from Omnicell's earnings call?

What is the market's earnings forecast for Omnicell next quarter?

Did Omnicell beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Omnicell year over year?

- **ARR Growth**: 2025 exit ARR of $636 million (+10% YoY), guided to $680-700 million in 2026.
- **Titan XT Opportunity**: $2.5 billion replacement cycle over 8+ years, with H2 2026 shipments.
- **Financial Resilience**: Q4 2025 total revenue above guidance, despite 4% YoY gross margin decline.
- **Tariff Mitigation**: $15 million 2026 impact, offset by supply chain optimization.
- **Recurring Revenue Focus**: 2026 service revenue growth expected to outpace product revenue.

**【CEO Summary Section】**
- **Q4 2025 Performance**: Total revenue of $314 million, above midpoint of guidance, driven by strong product and service revenue growth. ARR exited Q4 at $636 million, up 10% YoY.
- **Titan XT Launch**: Introduced at ASHP Annual Meeting, with early positive feedback from customers. Expected to be available for shipment in H2 2026.
- **Three Growth Pillars**: 
  1. **Market Expansion**: Penetrating inpatient and outpatient care settings with solutions like XTExtend and Titan XT.
  2. **Recurring Revenue**: SaaS and service contracts (e.g., OmniSphere) now at $636 million ARR.
  3. **Technology Platform**: OmniSphere, a cloud-based platform, achieved HITRUST certification and is being adopted across health systems.
- **Competitive Wins**: Secured deals with major health systems in Louisiana, Texas, and New England, driving patient safety and efficiency.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: 
  - Total revenue: $314 million (+2% YoY)
  - Non-GAAP EPS: $0.40 (down 33% YoY due to reduced interest income)
  - Non-GAAP EBITDA: $37 million (down 19% YoY)
  - Free cash flow: $18 million
- **2026 Guidance**: 
  - Product bookings: $510-560 million
  - Total revenue: $1.215-1.255 billion
  - ARR: $680-700 million
  - Non-GAAP EBITDA: $145-160 million
- **Tariff Impact**: Anticipated $15 million hit in 2026, partially offset by cost control.
- **Cash Position**: $197 million as of Q4 2025, after debt repayment and share buybacks.

**【Q&A Highlights】**
- **Titan XT Adoption**: Expected $2.5 billion replacement cycle over 8+ years, with early pipeline activity post-ASHP launch.
- **Gross Margin Challenges**: Q4 product margin decline due to mix shift and tariffs; service margins improved 1% QoQ.
- **Investments**: $10 million in ERP upgrades for 2026, supporting long-term efficiency.
- **Competitive Wins**: 40% of Q4 bookings from competitive upgrades, driven by OmniSphere's platform value.
- **Cloud Strategy**: XTExtend consoles enable cloud access, positioning for future OmniSphere adoption.


Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript

- **Revenue Beat**: Q3 revenue $311M (+10% YoY), Non-GAAP EPS $0.51 vs. $0.56 prior year. Full-year guidance raised to $1.177B-$1.187B.
- **OmniSphere Expansion**: 60+ customers migrating to cloud platform; early adopters report efficiency gains. HITRUST-certified security.
- **Tariff Mitigation**: $6M Q3 impact, 2025 total $15M. 2026 actions to reduce impact below Q4 2025 run rate.
- **Innovation Push**: Modular robots, AI-driven pharmacy solutions, and ASHP 2025 product showcase.
- **340B Growth**: Over 50% new contracts from existing customers, ARR $610M-$630M.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $311 million, up 10% YoY, driven by point-of-care solutions like XTExtend. Non-GAAP EPS was $0.51, exceeding expectations.
- **OmniSphere Momentum**: Cloud-based platform achieved HITRUST certification, with early adopters and plans for full customer migration. Expansion into outpatient settings and government facilities.
- **Strategic Pillars**: Market expansion (nursing units, ORs), service contracts (subscriptions, software), and technology acceleration (AI, robotics). Completed $75M stock buyback, reducing shares by 5%.
- **Innovation Focus**: Autonomous pharmacy vision with AI and robotics; new compounding robot in limited release. ASHP 2025 showcase for new innovations.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q3 GAAP EPS $0.12, Non-GAAP EPS $0.51. Gross margin 44.2%. Free cash flow $14M, down from $27M prior quarter. Tariffs impacted Q3 profitability by $6M, expected to continue in Q4.
- **Guidance Update**: Full-year revenue raised to $1.177B-$1.187B, up from $1.13B-$1.16B. Non-GAAP EBITDA $140M-$146M, up from $130M-$145M. ARR $610M-$630M.
- **Tariff Mitigation**: Supply chain diversification to reduce 2026 impact. Q4 revenue $306M-$316M, EBITDA $37M-$43M.

**【Q&A Highlights】**
- **Robotics & Hardware**: Exploring humanoid robots for pharmacy; smaller, modular dispensing robots in development. Robotics integration into current products for efficiency.
- **OmniSphere Adoption**: 60+ customers on OmniCenter migrating to OmniSphere. Early adopters report improved visibility and efficiency.
- **IV Opportunity**: Ballad Health win for IV workflow solutions. Hub-and-spoke model based on health system size and throughput needs.
- **340B Growth**: Over half of new 340B contracts from existing customers. Regulatory headwinds offset by hospital focus on ROI, ARR growth expected.
- **Sales Cycle**: Consistent pipeline momentum, no significant cycle changes. Focus on point-of-care products with limited release compounding robot.
- **Tariff Impact**: Q3/Q4 $6M net impact, 2025 total $15M. 2026 mitigation efforts to reduce impact below Q4 2025 run rate.

Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue $291M (+5% YoY, +8% QoQ), driven by XTExtend wins and MedVision/MedTrack launches.
- **Margin Expansion**: Non-GAAP gross margin 44.7% (up 260bps QoQ), EPS $0.45 (vs. $0.26 QoQ).
- **Tariff Mitigation**: $15M 2025 net impact; price increases gaining traction, 2026 impact expected to decline.
- **Innovation Momentum**: HITRUST-certified Omnisphere platform, MedVision for outpatient clinics, MedTrackOR RFID solution.
- **Guidance Update**: 2025 revenue raised to $1.13B-$1.16B, EBITDA to $130M-$145M.

**【CEO Summary Section】**
- Reaffirmed full-year 2025 guidance for product bookings and ARR, modestly raised revenue, EBITDA, and EPS targets.
- Q2 revenue of $291M (+5% YoY, +8% QoQ) driven by XTExtend wins in Northeast, Nebraska, and Southern New York.
- Introduced MedVision for outpatient clinics and MedTrackOR RFID solution for operating rooms.
- Omnisphere platform achieved HITRUST certification, positioning as the industry's only med management company with this standard.
- Emphasized long-term strategy to evolve from device-centric to end-to-end medication management platform.

**【CFO Financial Commentary】**
- Q2 non-GAAP EPS: $0.45 (vs. $0.51 YoY, $0.26 QoQ), GAAP EPS: $0.12 (vs. $0.08 YoY, -$0.15 QoQ).
- Gross margin: 44.7% (up 50bps YoY, 260bps QoQ) due to higher volumes, pricing, and mix.
- Tariff impact: $2M net in Q2, expected $6M/Q in H2, with 2025 total net impact of $15M.
- Free cash flow: $27M (vs. $10M QoQ), cash: $399M.
- Raised 2025 revenue guidance to $1.13B-$1.16B (prev: $1.105B-$1.155B), EBITDA to $130M-$145M (prev: $120M-$145M).

**【Q&A Highlights】**
- **Competitive Landscape**: CEO notes hospitals remain active buyers despite macro uncertainty; Omnicell's tech platform and enterprise solutions differentiate from competitors.
- **Medicaid Cuts**: No pipeline delays observed; customers view automation as cost-saving solution.
- **IV Automation**: Q2 win with leading Southern California health system; product backlog growing.
- **Tariff Mitigation**: Price increases gaining market acceptance; 2026 tariff impact expected to decline.
- **Omnisphere Adoption**: All customers will migrate to platform over several years; recurring revenue opportunities from SaaS, subscriptions.
- **Recurring Revenue**: 50-50 split between product and services; XT Amplify driving product growth, consumables up 8% QoQ.


Omnicell (OMCL)-31 Jul 25-2025 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2025 revenue up 9% YoY to $270M, driven by XT Amplify (product +8%, services +10%).
- **Margin Pressure**: Gross margin 42.1% vs. 47.4% prior quarter due to lower volumes and tariffs.
- **Tariff Risk**: $40M EBITDA impact in 2025, with $35M in H2. 3-year nearshore plan 1/3 complete.
- **Customer Momentum**: Secured multi-site contracts with top 10 health systems for point-of-care automation.
- **Financial Resilience**: $387M cash reserves, generating $10M free cash flow despite headwinds.


**【CEO Summary Section】**
- Total revenue for Q1 2025 was $270 million, up 9% YoY, driven by XT Amplify program growth and recurring services. Product revenue grew 8% YoY to $145 million, while service revenue increased 10% YoY to $125 million.
- Non-GAAP gross margin was 42.1%, down 530bps QoQ due to lower product volumes and seasonal expenses. Non-GAAP EPS was $0.26 vs. $0.03 YoY.
- Tariffs on China-sourced components could impact 2025 non-GAAP EBITDA by $40M, with $5M in Q2 and $35M in H2. Mitigation efforts include nearshoring and dual sourcing.
- Secured new contracts with leading health systems in NJ, IL, and RI for XT Cabinets, anesthesia workstations, and specialty pharmacy services.

**【CFO Financial Commentary】**
- Q1 2025 non-GAAP EBITDA was $24 million, up 13% YoY but down 48% QoQ. Free cash flow was $10 million, with cash reserves at $387 million.
- Updated 2025 guidance: Total revenue $1.105B-$1.155B, non-GAAP EBITDA $100M-$145M (down from prior $110M-$160M range). Non-GAAP EPS $1.00-$1.65 (down from $1.20-$1.80).
- Tariff mitigation plans include accelerating component shipments from low-tariff regions and evaluating pricing strategies.

**【Q&A Key Takeaways】**
- **Tariff Impact Distribution**: Company absorbing full $40M EBITDA impact in 2025, no price increases passed to customers yet. 
- **Supply Chain Transition**: 3-year nearshore plan 1/3 complete. Semiconductors and metal frames are key China-sourced components.
- **Demand Environment**: Hospitals prioritizing pharmacy IT for outpatient expansion and specialty meds. Q1 bookings remain strong despite macro concerns.
- **Product Momentum**: XT Amplify rollout on track, IBX software release gaining traction with 6%+ hospital margins driving investments.


Omnicell, Inc. (OMCL) Q1 2025 Earnings Conference Call Transcript

- **Revenue Recovery**: Q4 2024 revenue up 15% YoY to $307 million, with product revenue surging 37% YoY.
- **Profitability Breakthrough**: Q4 GAAP EPS of $0.34 marks return to GAAP profitability; Non-GAAP EBITDA up 17% YoY to $136 million.
- **Strategic Wins**: Secured multi-year contracts with NYC Health + Hospitals and a Fortune 25 insurer, expanding EnlivenHealth services.
- **2025 Growth Path**: Guided for $1.105-1.155 billion in 2025 revenue, with Non-GAAP EBITDA margin expansion of 100bps.
- **Robotics Momentum**: IVX Station robots now compatible with 60+ new drug vials, supporting 23% YoY growth in IVCS revenue.
- **ARR Acceleration**: Annual recurring revenue expected to grow to $610-630 million in 2025 (53% of total revenue), driven by specialty pharmacy and SaaS expansion.


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 total revenue of $307 million, up 15% YoY, driven by strong product revenue ($182 million, +37% YoY) and service revenue ($125 million, +11% YoY). 
- **Gross Margin Expansion**: Non-GAAP gross margin improved to 47.4% (vs. 44.5% Q3 2024), benefiting from higher product volumes and favorable mix.
- **Key Wins**: Secured multi-year contracts with NYC Health + Hospitals, North Carolina healthcare system, and a Fortune 25 health insurer for EnlivenHealth services.
- **2025 Outlook**: On track for consistent GAAP profitability, with Q1 2025 revenue guidance of $255-265 million and full-year total revenue of $1.105-1.155 billion.

**【CFO Financial Commentary】**
- **Profitability**: Q4 GAAP EPS of $0.34 (vs. -$0.32 Q4 2023), Non-GAAP EPS of $0.60 (vs. $0.33 Q4 2023). Full-year Non-GAAP EBITDA of $136 million exceeded revised guidance.
- **Cash Flow**: Q4 free cash flow of $43 million, ending 2024 with $369 million in cash. 2025 Non-GAAP EBITDA guidance of $140-155 million reflects 100bps margin expansion.
- **Bookings**: 2024 product bookings of $558 million (new metric), with 2025 guidance of $500-550 million. ARR expected to grow to $610-630 million (vs. $580 million 2024).

**【Q&A Highlights】**
- **Demand Trends**: Hospitals' improved financial health driving capital spending, with 2024 bookings up 79% YoY. XT Amplify adoption accelerating, with 60+ new NDCs enabled in IVX robots.
- **Gross Margin Leverage**: SaaS/Expert Services (14% YoY growth) and XTExtend (higher margins) driving margin expansion. 2025 gross margin expected to improve further.
- **Robotics Growth**: IVX Station installations expanding during IV fluid shortage, with 60+ new drug vial compatibilities added. Q4 2024 IVCS revenue up 23% YoY.
- **ARR Contribution**: SaaS/Expert Services now 53% of total revenue, with specialty pharmacy services growing double-digits. 2025 ARR expected to grow 5-7%.


Omnicell, Inc. (OMCL) Q4 2024 Earnings Call Transcript

Omnicell (OMCL)-30 Oct 24-2024 Q3 Earnings call transcript

Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript

Omnicell (OMCL)-2 May 24-2024 Q1 Earnings call transcript

Omnicell (OMCL)-8 Feb 24-2023 Q4 Earnings call transcript

- **Strong Q2 Results**: Revenue of $299 million, non-GAAP EPS of $0.57, and EBITDA of $47 million beat expectations, driven by services growth and cost management.
- **Customer Momentum**: Expansion of inventory optimization to 20 hospitals, IV compounding adoption, and competitive conversions highlight strong demand for automation solutions.
- **Guidance Update**: Full-year revenue raised to $1.16-1.2 billion, with advanced services expected to grow 13% YoY.
- **Cost Efficiency**: $50 million annual savings from cost actions, with full impact in H2, supporting flat to down operating expenses.
- **AI and Innovation**: Internal AI use cases for efficiency, cautious external deployment, and no immediate M&A plans.
- **Headwinds**: Labor shortages and regulatory uncertainty delaying advanced service adoption, with bookings guided to lower end of range.


**【CEO Summary Section】**
- **Q2 2023 Performance**: Total revenue of $299 million, exceeding guidance due to higher technical and advanced services revenue, favorable customer mix, and cost management. Non-GAAP EPS of $0.57 and non-GAAP EBITDA of $47 million also beat expectations.
- **Customer Wins**: Expansion of inventory optimization services to 20 hospitals in the South, adoption of IV compounding services in Florida, and competitive conversions in Minnesota and California. A northeast pharmacy chain saw a 17% reduction in call transfers using live health IVR.
- **Market Challenges**: Labor shortages and budget constraints delaying new technology adoption, particularly in advanced services. Full-year bookings expected at the lower end of $1.0-1.1 billion range.
- **Guidance Update**: Full-year revenue raised to $1.16-1.2 billion, with service revenue guidance increased by $10 million. Advanced services expected to grow 13% YoY.
- **Leadership Changes**: Addition of Bobby Ghoshal to the board and Nchacha Etta as CFO, with organizational restructuring to enhance operational efficiency.

**【CFO Financial Commentary】**
- **Q2 Financials**: GAAP net income of $0.08, up from a loss in Q1. Non-GAAP EBITDA of $47 million, up 200 basis points in gross margin due to higher services revenue and cost containment. Cash balance increased to $399 million.
- **Cost Management**: $50 million annual operating expense savings from RIF and cost actions, with full impact expected in H2. Non-GAAP operating expenses flat to down YoY.
- **Tax Impact**: Higher than expected Q2 tax expense due to timing, with improvement expected in H2. Full-year blended tax rate of 11%.
- **Q3 Guidance**: Revenue $290-300 million, non-GAAP EBITDA $31-37 million, EPS $0.42-0.52.

**【Q&A Highlights】**
- **Operating Expenses**: SG&A down 17% QoQ due to $50 million cost savings, with full impact in H2. Labor constraints at hospitals delaying advanced service adoption.
- **Booking Challenges**: Regulatory uncertainty in IV compounding and macroeconomic uncertainty affecting customer spending. Full-year bookings guided to lower end of range.
- **AI Strategy**: Internal use cases for efficiency, with cautious external deployment due to regulatory considerations. No immediate M&A plans.
- **Product Margins**: Favorable mix and pricing actions offsetting semiconductor cost reductions. XT upgrades nearing completion, with no immediate new product cycle.
- **CMS Payment**: $9 billion rebate expected in Q4/Q1, potentially accelerating hospital spending on automation solutions.


Actual											0.66	0.37	0.6	0.91	0.83	0.97	1.08	0.92	0.83	0.84	1	0.33	0.39	0.57	0.62	0.33	0.03	0.51	0.56	0.6	0.26	0.45	0.51	0.4
Forecast											0.5117	0.2288	0.4871	0.8114	0.6567	0.8267	0.9125	0.923	0.685	0.85	0.9544	0.0822	0.0676	0.2822	0.4657	0.1539	-0.0932	0.1443	0.4192	0.5835	0.2046	0.27	0.3625	0.4963
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+28.98%	+61.71%	+23.18%	+12.15%	+26.39%	+17.33%	+18.36%	-0.33%	+21.17%	-1.18%	+4.78%	+301.46%	+476.92%	+101.98%	+33.13%	+114.42%	+132.19%	+253.43%	+33.59%	+2.83%	+27.08%	+66.67%	+40.69%	-19.40%

OMCL

OMCL fundamentals

OMCL Q4 2025 Earnings

Earnings Call

You can ask Aime

OMCL

OMCL fundamentals

OMCL Q4 2025 Earnings

Earnings Call

OMCL Earnings Call Summary for Q4/20258:30 AM on Feb 5, 2026

OMCL Earnings Call Summary for Q3/20258:30 AM on Oct 30, 2025

OMCL Earnings Call Summary for Q2/20258:30 AM on Jul 31, 2025

OMCL Earnings Call Summary for Q1/20258:30 AM on May 6, 2025

OMCL Earnings Call Summary for Q4/20248:30 AM on Feb 6, 2025

You can ask Aime